The Danish pharmaceutical giant said the drug was more effective than a daily growth hormone in children with Noonan syndrome--a genetic condition that stops typical development in some parts of the ...

In Noonan syndrome, Sogroya achieved 10.4 cm/year height gain vs 9.2 cm/year with daily somatropin. Don’t miss this list of 3 high-yield stocks—including one delivering over 10%—built for ...

N) today presented data from the Phase III REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was ...

The Danish pharmaceutical giant said the drug was more effective than a daily growth hormone in children with Noonan syndrome--a genetic condition that stops typical development in some parts of ...